Plasma processing device with anaphylatoxin remover

• US 4,963,265 A
• Filed: 05/06/1988
• Issued: 10/16/1990
• Est. Priority Date: 05/06/1988
• Status: Expired due to Fees

• Current Assignee: Applied Immune Sciences, Inc. (Sanofi )
• Original Assignee: Applied Immune Sciences, Inc. (Sanofi )
• Inventors: Chang, Chin-Hai, Clark, Brian R., Okarma, Thomas B., Lerch, L. Bernard
• Primary Examiner(s): Jones, W. Gary
• Application Number:
  US07/191,039
• Time in Patent Office: 893 Days
• Field of Search: 210/634, 210/635, 210/638, 210/645, 210/646, 210/651, 210/660, 210/691, 210/321.72-321.9, 210/502.1, 210/908, 604/4, 604/5, 604/6, 530/380, 530/412, 424/101, 502/407, 502/410
• US Class Current: 210/638
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: Y10S 210/908 Organic

Abstract

Blood derived fluids are subjected to modification resulting in the production of anaphylatoxins. The anaphylatoxins may then be removed by passing the modified blood through silicic acid particles in an amount sufficient to substantially reduce the anaphylatoxins, while still retaining the other blood components and without affecting adversely the use of the blood for the patient.

Claims

1. A method for reducing elevated levels of anaphylatoxins in a blood derived fluid consisting of serum or plasma having an initial level of at least one of the anaphylatoxins at least two times greater than the original blood level of anaphylatoxins comprising:

contacting said fluid with an anaphylatoxin reducing amount of silicic acid.

2. A method according to claim 1, wherein said silicic acid is present in an amount of from about 10 to 100 g/L of fluid treated.

3. A method according to claim 1, wherein said silicic acid is characterized by having a pH in the range of about 4 to 7, a size in the range of about 50 to 400 μ

, a pore size in the range of about 50 to 350 Å

, and a surface area of at least about 200 m² /g.

4. A method for treating blood to be administered to a mammalian host, said method comprising:

preparing plasma from said blood;

selectively changing the composition of said plasma by contacting said plasma with a membrane which specifically affects the composition of said plasma, whereby the level of anaphylatoxins may be increased; and

contacting said plasma with silicic acid characterized by being capable of substantially selectively removing proteins having molecular weights in the range of about 15 to 50 kD and having a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylotoxins to at least substantially the original level of said plasma.

5. A method according to claim 4, wherein said membrane is an affinity membrane to which is covalently bonded a member of a specific binding pair homologous to said component.

6. A method according to claim 5, wherein said specific binding pair member is an antibody.

7. A method for treating a person to change the level of a blood component, said method comprising:

removing blood from said person and separating plasma from said blood;

selectively removing at least one component of said plasma by contacting said plasma with a membrane which specifically modifies the concentration of said component, whereby the level of anaphylatoxins may be increased; and

contacting said plasma with silicic acid characterized by substantially selectively removing proteins having a molecular weight in the range of about 15 to 50 kD and a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylatoxins to at least substantially the original level of said plasma in said first compartment.

8. A method according to claim 7, wherein said silicic acid is characterized by having a pH in the range of about 4 to 7, pore size in the range of about 50 to 350 Å

, an average particle size in the range of about 50 to 400 μ

, and a surface area of at least about 200 m² /g.